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Abstract 
Purpose: To investigate anticancer effects of bergenin on human colorectal cancer cell lines. 
Methods: Human colorectal adenocarcinoma cell line HCT116 was treated with various concentrations 
of bergenin for 24 and 48 h. Cell viability, apoptosis, cell cycle arrest and reactive oxygen species 
(ROS) level were analyzed by MTT, flow cytometry and fluorescent dye assays, respectively. DNA 
damage-associated protein expressions were analyzed by Western blotting. 
Results: Bergenin significantly suppressed the viability of HCT116 cells. Moreover, bergenin induced 
cells to accumulate in G1 phase and resulted in DNA breaks in HCT116 cells. It also led to marked 
accumulation of intracellular reactive oxygen species (ROS), a breaker of DNA strand in HCT116 cells. 
Interestingly, bergenin inhibited PI3K/AKT/mTOR pathway. 
Conclusion: Bergenin effectively suppresses the growth of colorectal adenocarcinoma by inducing 
generation of intracellular ROS, DNA damage and consequent G1 phase arrest via inhibition of 
PI3K/AKT/mTOR pathway. 
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Colorectal cancer (CRC) is the third most 
common cancer and the fourth most common 
cause of cancer-related death, with between one 
and two million new cases being diagnosed 
every year, and its incidence has been 
increasing year by year [1]. Modifiable risk 
factors for CRC relating to lifestyle include 
smoking, physical activity habits, overweight, 
obesity and alcohol consumption. Chemotherapy 
and surgery are the most common treatment for 
CRC [2]. With the development and application 
of a new generation of chemotherapy and 
molecular-targeted drugs, the effects of CRC 
treatment have improved, but are still 
unsatisfactory. In addition, the toxic side effects 
of chemotherapy drugs and the failure of 
chemotherapy due to drug resistance are some 
of the drawbacks of clinical treatment [3].  
 
Bergenin, an active constituent of the herb of 
Bergenia purpurascens (Hook. f. et Thoms.) 
Engl. has been widely used as an active anti-
inflammatory ingredient, which can inhibit chronic 
bronchitis, and attenuates chronic gastritis 
clinically [4,5]. Moreover, studies have reported 
that bergenin has various bioactivities, such as 
hepatoprotective [6], neuroprotective [7] and 
antioxidant properties [8]. Despite bergenin being 
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known for its multifaceted activities, the anti-
colorectal carcinoma activity has not been 
studied. 
 
The present study was designed to explore its 
efficiency in inhibition of cell growth in human 
colorectal carcinoma cells. In view of the effects 
on the activation of PI3K/AKT/mTOR pathway, 
the underlying mechanisms of how bergenin 





Chemicals and reagents 
 
Bergenin (C14H16O9, MW: 328.27, purity ≥ 98 %) 
was purchased from Sigma-Aldrich (St. Louis, 
MO, USA). Bergenin was dissolved in 
dimethylsulfoxide (DMSO) as stock solution of 
0.1 M, stored at -20 °C, and freshly diluted with 
RPMI-1640 medium (Gibco, Carlsbad, CA, USA) 
to the final concentration used in the study. MTT 
[3-(4, 5-dimethylthiazol-2-yl)-2, 5-dipheny-
tetrazoliumbromide] and N-acetyl-l-cysteine 
(NAC) were obtained from Sigma-Aldrich. 
Antibodies against p-AKT (Ser473), total AKT, p-
mTOR (Ser2448), total mTOR and GAPDH were 
purchased from Bioworld Technology, Inc. (Louis 
Park, MN, USA). p-H2AX (Ser139), H2AX 
antibodies were purchased from EnoGene 
Biotech (Nanjing, China). Other chemical 




Human colorectal adenocarcinoma HCT116 cell 
line was obtained from American Type Culture 
Collection (Bethesda, MD, USA). Cells were 
cultured in RPMI-1640 medium (Gibco), 
supplemented with 10 % fetal bovine serum 
(Gibco), 100 U/mL benzyl penicillin and 100 
mg/mL streptomycin. Cells were cultured in a 
humidified environment with 5 % CO2 at 37 °C.  
 
Cell viability assay 
 
Cell viability was measured using the colorimetric 
MTT assay as described previously [9,10]. The 
cells were incubated overnight and then treated 
with various concentrations of bergenin, and 
incubated for 24 and 48 h. Subsequently, 20 μL 
of MTT solution (5 mg/mL) was added to each 
well. The plate was incubated at 37 °C in a 5 % 
CO2 atmosphere for 4 h, the supernatants were 
removed and 150 μL/well DMSO was added then 
placed in an orbital shaker for 5 min, and the 
absorbance was recorded at 570 nm with a 
Model 1500 Multiskan spectrum microplate 
reader (Thermo, Waltham, MA, USA). Data were 
analyzed from three independent experiments 
and then normalized to the absorbance of the 
wells containing media only (0 %) and untreated 




HCT116 cells were treated with various 
concentrations of bergenin and were harvested 
by trypsinization and then washed twice with 
PBS. Cells were stained with Annexin V-FITC 
and PI, and then analyzed with a FACSCalibur 
flow cytometer using Cell Quest software (BD 
Bioscience, San Jose, CA, USA). Results were 
analyzed using Flowjo 7.6 software (Treestar, 
Ashland, OR, USA). 
 
Cell cycle analysis 
 
HCT116 cells were treated with various 
concentrations of bergenin and were harvested 
by trypsinization, fixed with 70 % ethanol and 
stored at -20 °C for at least 1 day. Following 
fixation, cells were subjected to a PBS wash and 
then stained with DNA staining solution 
comprising 2.5 mg/mL propidium iodide (PI) and 
50 mg/mL RNaseA in PBS. Samples were 
incubated at 37 °C for 30 min away from light 
and then analyzed on a FACSCabibur flow 
cytometer (BD Bioscience) [9]. Results were 




Whole cell lysates from HCT116 cells were 
prepared by suspending cells in NP40 buffer. 
The equal concentration of protein lysate of all 
the samples was separated on 8 % SDS-PAGE 
gel and further transferred to nitrocellulose 
membranes. The membranes were blocked with 
5 % nonfat milk for 2 h, and incubated overnight 
at 4 °C with specific primary antibodies against 
p-AKT (Ser473), AKT, p-mTOR (Ser2448), 
mTOR, p-H2AX (Ser139), H2AX and GAPDH, 
and then incubated with IRDye-conjugated 
secondary antibody for 1 h at 37 °C. Detection 
was performed by the Odyssey Infrared Imaging 
System (LI-COR, Inc., Lincoln, MT, USA). 
 
Measurement of ROS level 
 
The production of cellular reactive oxygen 
species (ROS) was detected using fluorescent 
dye, 2, 7-dichlorofluoresceindiacetate (DCFH-
DA, Beyotime Institute of Biotechnology, China) 
as previously described [11]. In brief, HCT116 
cells were pretreated with/without NAC for 2 h 
and then exposed to bergenin for 12 h. Then 
cells were collected and incubated with 10 μM 
DCFH-DA attenuated with serum-free medium 
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for 30 min at 37 °C in the dark. After washing 
with serum-free medium, ROS level was 
measured by intensity of the fluorescence 
produced on a Model 1500 Multiskan spectrum 




Data are presented as mean ± SEM (n = 3). Data 
sets were performed using one-way analysis of 
variance (ANOVA) followed by Dunnett's test 
between control and experimental groups. P < 




Effect of bergenin on growth of human colon 
cancer cells 
 
At first, we examined the effect of bergenin at 
different concentrations on cell viability. As 
shown in Figure 1, after 24 and 48 h of 
treatment, bergenin markedly inhibited the cell 
growth in HCT116 cells in a concentration-
dependent manner. 
 
Effect of bergenin on cell apoptosis in colon 
cancer cells 
 
We next evaluated apoptosis in HCT116 cells 
after treatment with 3, 10 and 30 μM bergenin for 
24 h, the percentage of total apoptosis cells were 
2.53 ± 0.51 %, 5.21 % ± 0.93 %, 8.56 ± 1.02 % 
and 14.87 ± 1.35 %, respectively (Figure 2).  
 
 
Figure 1: Effect of bergenin on the growth of human 
colon cancer cells. HCT116 cells were incubated with 
various concentrations of bergenin (1, 3, 10, 30 μM) 
for 24 and 48 h, and cell viability was analyzed by 
MTT assay. Data were presented as means ± SEM of 
three independent experiments; *p < 0.05, **p < 0.01 
vs control 
 
Effect of bergenin on cell cycle in colon 
cancer cells 
 
Because of the significant inhibitory effect on cell 
viability and growth, we estimated the effect of 
bergenin on the distribution of cells in the cell 
cycle. As shown in Figure 3, bergenin (3, 10, 30 
μM) treatment led to an increase in the number 
of cells in the G1 phase with decreased 




Figure 2: Effect of bergenin on cell apoptosis in colon cancer cells. HCT116 cells were incubated with 
various concentrations of bergenin (3, 10, 30 μM) for 24 h, and cell apoptosis was stained with 
Annexin V/PI followed by flow cytometry. The percentages of cells in apoptosis were represented. 
Data were presented as means ± SEM of three independent experiments; *p < 0.05, **p < 0.01 vs 
control
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data showed that the number of cells in the G1 
phase was 1.5-fold and 2-fold at 10 and 30 μM at 
24 h, respectively. 
 
 
Figure 3: Effect of bergenin on the cell cycle in colon 
cancer cells. HCT116 cells were incubated with 
various concentrations of bergenin (3, 10, 30 μM) for 
24 h, and the cell cycle was analyzed by flow 
cytometry after staining with propidium iodide. Cells in 
G0/G1, S and G2/M phases were quantified and 
presented. Data were presented as means ± SEM of 
three independent experiments; *p < 0.05, **p < 0.01 
vs control 
 
Effect of bergenin on DNA damage 
 
We investigated the phosphorylation of histone 
variant H2AX at Ser139, an indicator of DNA 
break. As shown in Figure 4, bergenin markedly 
increased the level of phosphorylated H2AX at 
Ser139 in a concentration-dependent manner. 
The results indicated that bergenin might lead to 
DNA damage in HCT116 cells. 
 
Effect of bergenin on ROS level 
 
To investigate the effect of bergenin on ROS 
generation, we detected the levels of ROS in 
bergenin-treated cells. It was shown that 
bergenin (10 and 30 μM) treatment induced a 
substantial increase in ROS levels in HCT116 
cells at 24 h. In addition, NAC (a ROS 
scavenger) markedly decreased the 
accumulation of ROS induced by bergenin 
(Figure 5). 
 
Effect of bergenin on activation PI3K/AKT/ 
mTOR pathway 
 
The canonical PI3K/AKT/mTOR signaling 
pathway has emerged as a critical regulator 
pathway of cell proliferation [1].  
 
 
Figure 4: Effect of bergenin on DNA damage. 
HCT116 cells were incubated with various 
concentrations of bergenin (3, 10, 30 μM) for 24 h. Cell 
were harvested and lysed, and the levels of p-H2AX, 
H2AX and GAPDH were analyzed by immunoblotting. 
Densitometry analysis of immunoblotting was also 
shown. Data were presented as means ± SEM of 





Figure 5: Effect of bergenin on ROS level. HCT116 
cells were pretreated with/without NAC for 2 h and 
then exposed to various concentrations of bergenin (3, 
10, 30 μM) for 12 h. ROS level was tested with 
fluorescence probe DCFH2-DA. Data were presented 
as means ± SEM of three independent experiments; 
*p < 0.05, **p < 0.01 vs control. #p < 0.05 vs the 
indicated 
 
Our former data showed that bergenin could 
down-regulate cell viability and growth, thus we 
tested the effect of bergenin on PI3K/AKT/mTOR 
signaling pathway. Western blot analysis showed 
that bergenin markedly decreased the 
phosphorylation levels of AKT and mTOR, while 
it had no significant effect on the total levels of 
AKT and mTOR in a concentration-dependent 
manner (Figure 6). 
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Figure 6: Effect of bergenin on the activation PI3K/AKT/mTOR pathway. HCT116 cells were incubated with 
various concentrations of bergenin (3, 10, 30 μM) for 24 h. Cell were harvested and lysed, and the levels of p-
AKT, AKT, p-mTOR and mTOR were analyzed by immunoblotting. Densitometry analysis of immunoblotting was 





CRC is one of the most common causes of 
cancer mortality. Traditional Chinese medicines 
have been recognized as new source of 
anticancer drugs as well as new chemotherapy 
adjuvants that enhance efficacy and diminish 
side effects of chemotherapeutic agent. In this 
study, bergenin showed significant inhibitory 
effect on the growth of HCT116 cells. Bergenin 
induced ROS-mediated DNA damage, which 
resulted in G1 phase arrest and inhibited the 
activation of PI3K/AKT/mTOR pathway. 
 
Bergenin could significantly inhibit HCT116 cell 
proliferation and growth in a concentration- and 
time-dependent manner, which demonstrated 
that bergenin was a potent cytotoxic compound. 
Cell cycle is the essential mechanism by which 
all cells reproduce. New links between alterations 
in the cell cycle regulatory machinery and 
tumorigenesis are being constantly reported and 
virtually all molecular species involved in 
regulating cell proliferation described in the 
literature have been related to malignant 
transformation [12]. Thus, we assumed that 
bergenin-induced cell growth inhibition was due 
to cell cycle arrest. We found that bergenin 
induced concentration-dependent G1 phase cell 
cycle arrest in HCT116 cells. In advanced CRC, 
cancer cells usually become resistant to 
apoptosis [13]. Thus, identification that bergenin 
that can induce apoptosis in CRC cells is highly 
desirable. The results showed bergenin 
treatment for 24 h in HCT116 cells led to an 
elevated percentage of apoptotic cells. 
 
Many drugs in use disrupt genome integrity by 
causing DNA strand breaks, and consequently 
block cell proliferation mainly by suppressing 
factors that enable cells to proceed from one cell 
cycle phase to the next through checkpoints in 
the cell division cycle [14]. Then, we 
hypothesized that bergenin induced DNA 
damage, leading to G1 cell cycle arrest and 
apoptosis. The data showed that bergenin 
induced DNA damage in HCT116 cells in a 
concentration-dependent manner as confirmed 
by the increased level of p-H2AX (Ser139), the 
biomarker for DNA damage. 
 
Accumulative data have indicated that induction 
of DNA damage by high levels of ROS can 
induce cell cycle arrest and apoptosis [15,16]. In 
normal cells, ROS are at low levels, which are 
important for the regulation of normal cell 
proliferation. However, cancer cells, which exhibit 
much higher levels of ROS close to the threshold 
of cytotoxicity, are susceptible to ROS-
generating agents [17,18]. In this study, bergenin 
led to a marked increase in ROS levels in 
HCT116 cells. 
 
PI3K/AKT/mTOR pathway is a particularly 
important pathway that has also been involved in 
regulating cell proliferation, cell cycle 
progression, apoptosis and morphogenesis in 
different organs [19,20]. Earlier work established 
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that PI3K/AKT/mTOR signaling pathway plays a 
critical role in the development of human cancer 
including colorectal cancer [21]. Thus, to 
suppress the excessive activation of 
PI3K/AKT/mTOR signaling pathway is a key 
therapeutic method of colorectal cancer. Our 
data demonstrated that bergenin could markedly 





The findings demonstrate that cell growth 
inhibition and G1 phase arrest occur in colorectal 
carcinoma cells HCT116 exposed to bergenin. 
Bergenin efficiently induces the generation of 
intracellular ROS, DNA damage and consequent 
G1 phase arrest and inhibition of activation of 
PI3K/AKT/mTOR pathway. These results provide 
new insights into the anti-cancer mechanisms of 
bergenin, which may be helpful in the potential 
development of bergenin into a promising 
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